Related Experiment Video
Updated: Aug 19, 2025

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
Published on: February 28, 2019
A stable, engineered TL1A ligand co-stimulates T cells via specific binding to DR3
Adam Zwolak1, Szeman Ruby Chan2, Paul Harvilla3
1Biologics Discovery, Janssen Research & Development, LLC, Spring House, PA, 19477, USA. azwolak1@its.jnj.com.
Abstract:
TL1A (TNFSF15) is a TNF superfamily ligand which can bind the TNFRSF member death receptor 3 (DR3) on T cells and the soluble decoy receptor DcR3. Engagement of DR3 on CD4+ or CD8+ effector T cells by TL1A induces downstream signaling, leading to proliferation and an increase in secretion of inflammatory cytokines. We designed a stable recombinant TL1A molecule that (1) displays high monodispersity and stability, (2) displays the ability to activate T cells in vitro and in vivo, and (3) lacks binding to DcR3 while retaining functional activity via DR3. Together these results suggest the TL1A ligand can be amenable to therapeutic development on its own or paired with a tumor-targeting moiety.

